Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (February 2015)

25 slides from Enumeral Biomedical's investor presentation, Feb 23, 2015

  1. Slide 1: The Power of Human

    Slide 1: The Power of Human

    President and CEC ENUWERKL

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Loo OTC QB: ENU THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY'S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS EST

  3. Slide 3: Enumeral's Mission

    Slide 3: Enumeral's Mission

    | Enumeral’s Missio} Discover and Develop Best-In-Class Antibody Immunotherapies Using Our Proprietary Platform that Uniquely Leverages Human Cell Biology ENUNERAL rr

  4. Slide 4: Enumeral Opportunity

    Slide 4: Enumeral Opportunity

    at Enumeral Oppor * Developing pipeline of antibody product candidates modulating Tumor-Infiltrating Lymphocyte (“TIL”) function * Checkpoint modulators derived from proprietary target- specific antibody libraries * Proprietary ‘immune system on a chip’ platform guides human-based validation of opti

  5. Slide 5: Enumeral opportunities using Enumeral discovery technology

    Slide 5: Enumeral opportunities using Enumeral discovery technology

    Enumeral opp s using Enumeral iscovery technology Preciil feay FTE ‘opportunities to ‘0x40 Screening Jf Preclinical Efficacy ‘enter into co- development Lag-3 Screening Preclinical Efficacy Partnerships: Enumeral business VISTA Screening Preclinical Efficacy GeeeP *Enumeral intends to enter into co-

  6. Slide 6: Immunotherapy Field

    Slide 6: Immunotherapy Field

    Immunotherapy fF « Immunotherapy predicted to generate sales of up to $35 billion per year over next 10 years and treat up to 60% of all cancers* * Yervoy proves clinical and commercial success is tenable - launched in 2011, >$1B in revenue year ended June 30th, 2014** * Strong interest among pharma

  7. Slide 7: Enumeral's Platform

    Slide 7: Enumeral's Platform

    Proprietary Harvard and MIT-developed high-density bio-chip and one-day process measures key parameters of function of individual immune cells from patient samples: Determine cell function through cell secretions Determine cell type and biological function Recover cells of interest and gene sequence

  8. Slide 8: Human is Best: Models do not predict human response to immunotherapies

    Slide 8: Human is Best: Models do not predict human response to immunotherapies

    Human is Be © not predict human re se to Immunotherapies Conventional Approach Enumeral’s Differentiated Approach ENUNERAL

  9. Slide 9: Why is it Difficult: Immunotherapies

    Slide 9: Why is it Difficult: Immunotherapies

    Why is it Difficult: Immunotherapi ‘Mechanisms of action’ difficult to measure > Immunotherapy changes ‘behavior’ of immune system Disease ‘models’ not predictive > Research models are not predictive of human disease Rare human cells that underlie disease processes > Difficult to enumerate with curr

  10. Slide 10: Enumeral's technology enables measurement of targets on TILs

    Slide 10: Enumeral's technology enables measurement of targets on TILs

    Enumeral's technology enables measurement of targets on TILs in human biopsy samples Unbiased identification of rare cells Identified by function notmarkers No sorting or | enrichment 1000 secretion events @: Segmented by cytokine secretion ‘py, as as Markers Determine identity of secreting cells, V

  11. Slide 11: Enumeral's human approach to target validation and antibody selection

    Slide 11: Enumeral's human approach to target validation and antibody selection

    Enumeral’s hu validation and | o> =p =p OOOO O00 Antibodies and bispecifics Validate Antibodies from ENUM targets on TILs proprietary libraries PD-1 Selected based on predicted ooo0 0x40 effects from ex vivo human [Indication 1] . Tim3 studies [Indication 2] ip VISTA [Indication 3] Lag-3 Format depe

  12. Slide 12: First program selection output: PD-1

    Slide 12: First program selection output: PD-1

    e tii : = First program se utput: PD-1 Rapid generation of broad diversity of antibody sequences Potential for strong intellectual property around validated targets SR oa 11-12 Heavy chain AA sequences from PD1 EN UXe RAL N= 349 sequences; 28 families of antibodies

  13. Slide 13: Enumeral's platform selecting potent antibodies

    Slide 13: Enumeral's platform selecting potent antibodies

    Enumeral’s n selecting potent Antibody (IFNg secretion) (IENg secretion) (IFNg secretion) (IFNg secretion) (IFNg secretion) ENUM_1 ENUM_2 ENUM_3 Reference Potential PD- expression, by cell type: *Patent pending Oumnpgag ERAL

  14. Slide 14: Anti-PD-1 antibodies and additional programs

    Slide 14: Anti-PD-1 antibodies and additional programs

    * Anti-PD-1 antibodies First program reached initial preclinical validation of lead candidates; supports potential programs in cancer and inflammatory disease Partnering conversations initiated * Additional programs OX40 and Lag-3 screening ongoing Tim3 and VISTA initiated Q1 2015 Additional program

  15. Slide 15: Anti-PD-1 key question: What is the drug mechanism?

    Slide 15: Anti-PD-1 key question: What is the drug mechanism?

    Anti-PD-1 key questi Vhat is the drug mechanism?” * Ipilimumab, Nivolumab - Do these drug ‘deplete’ cells? Induce anergy? Induce apoptosis? Activate T cells? What else happens? ~ Why are these agents active in melanoma but not in colorectal cancer? ~ What accounts for patient variability in efficacy

  16. Slide 16: Can PD-1 be a target outside of oncology?

    Slide 16: Can PD-1 be a target outside of oncology?

    * Can PD-1 be a target outside of oncology? . ~ Are psoriasis, inflammatory bowel disease, or rheumatoid arthritis T cell diseases? Is the (presumed) IL-17 or « BT Autoimmune IFNy coming from pathologic — T cells? Is the disease etiology universal or variable across patients? Enu meral’s platfo rm:

  17. Slide 17: Enumeral Business Model

    Slide 17: Enumeral Business Model

    Enumeral Busine Generate near-term revenue and long-term value creation Multiple corporate partnering discussions g Partn =_ pes | . . Pharma Oncology Strategic partnerships ae ‘Autoimmune * Out-licensing and co-development ee ae * Patient response stratification Big Biotech Various * Resurrection o

  18. Slide 18: Enumeral and Merck Collaboration

    Slide 18: Enumeral and Merck Collaboration

    for Predicti ng Enumeral and Merc Formc Clinical Drug Response. Immune Profiling Platform * December 18, 2014 * Oncology-focused collaboration using Enumeral's human approach to interrogate the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify f

  19. Slide 19: Recent Achievements

    Slide 19: Recent Achievements

    Recent Achievem * Collaboration deal signed with top immuno-oncology’ pharmaceutical company (Merck, December 18, 2074) * Awarded $1M Phase II SBIR contract from the National Cancer Institute for technology development for human immuno-oncology profiling (September 2014) * Established collaboration

  20. Slide 20: Near-term Corporate Milestones

    Slide 20: Near-term Corporate Milestones

    Near-term Corpo 2015 (1H): ~ Sign additional corporate partnership Achieve key human ex vivo preclinical milestone in lead program (PD-1) 2015 (2H): Commence IND-enabling studies in first program (with a partner) Sign additional corporate partnership Achieve key human ex vivo preclinical milestones

  21. Slide 21: Management Team

    Slide 21: Management Team

    John J. Rydzewski, Executive Chairman, Co-Founder, Director Co Chair, RAND Healthcare Advisory Board, Christofferson-Robb, Kidder-Peabody, Price Waterhouse & Co., Wharton Arthur H. Tinkelenberg, Ph.D., President & CEO, Co-Founder, Director Ascent Biomedical Ventures, Robertson-Stephens, Columbia, Ro

  22. Slide 22: Board of Directors and Advisors

    Slide 22: Board of Directors and Advisors

    John J. Rydzewski, Executive Chairman, Co-Founder Arthur H. Tinkelenberg, Ph.D., President & CEO, Co-Founder Barry Buckland, Ph.D., Co-Founder, Co-Chairman of the Scientific Advisory Board Merck's bioprocess R&D Group; launched immunotherapy products, including GARDASIL, ROTATEQ, and ZOSTAVAX Allan

  23. Slide 23: Summary

    Slide 23: Summary

    Summary: immunotherapy ~ Platform for developing best-in-class product candidates based on a fundamental understanding of target physiology in human cells * Unique ex vivo ‘human approach’ for antibody candidate selection using patient-derived biopsy samples « Understanding of target physiology acro

  24. Slide 24: Financials & Capitalization

    Slide 24: Financials & Capitalization

    Financials & Capitalization Category ; Enumeral: uniquely positioned C Sh: 0 di 51,591,710 to address unmet needs in ommonshares Outstanding! ian expanding market for discovery Warrants Outstanding* 24,803,409 and development of novel Options Outstanding 2,374,420 immunotherapies UEOIREN, CEH] (Geli

  25. Slide 25

    Slide 25

Source: SEC EDGAR · 8-K filed Feb 23, 2015

More decks from Enumeral Biomedical Holdings Inc